» Articles » PMID: 27064003

Secondary Metabolites from Cetrarioid Lichens: Chemotaxonomy, Biological Activities and Pharmaceutical Potential

Overview
Journal Phytomedicine
Date 2016 Apr 12
PMID 27064003
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Lichens, as a symbiotic association of photobionts and mycobionts, display an unmatched environmental adaptability and a great chemical diversity. As an important morphological group, cetrarioid lichens are one of the most studied lichen taxa for their phylogeny, secondary chemistry, bioactivities and uses in folk medicines, especially the lichen Cetraria islandica. However, insufficient structure elucidation and discrepancy in bioactivity results could be found in a few studies.

Purpose: This review aimed to present a more detailed and updated overview of the knowledge of secondary metabolites from cetrarioid lichens in a critical manner, highlighting their potentials for pharmaceuticals as well as other applications. Here we also highlight the uses of molecular phylogenetics, metabolomics and ChemGPS-NP model for future bioprospecting, taxonomy and drug screening to accelerate applications of those lichen substances.

Chapters: The paper starts with a short introduction in to the studies of lichen secondary metabolites, the biological classification of cetrarioid lichens and the aim. In light of ethnic uses of cetrarioid lichens for therapeutic purposes, molecular phylogeny is proposed as a tool for future bioprospecting of cetrarioid lichens, followed by a brief discussion of the taxonomic value of lichen substances. Then a delicate description of the bioactivities, patents, updated chemical structures and lichen sources is presented, where lichen substances are grouped by their chemical structures and discussed about their bioactivity in comparison with reference compounds. To accelerate the discovery of bioactivities and potential drug targets of lichen substances, the application of the ChemGPS NP model is highlighted. Finally the safety concerns of lichen substances (i.e. toxicity and immunogenicity) and future-prospects in the field are exhibited.

Conclusion: While the ethnic uses of cetrarioid lichens and the pharmaceutical potential of their secondary metabolites have been recognized, the knowledge of a large number of lichen substances with interesting structures is still limited to various in vitro assays with insufficient biological annotations, and this area still deserves more research in bioactivity, drug targets and screening. Attention should be paid on the accurate interpretation of their bioactivity for further applications avoiding over-interpretations from various in vitro bioassays.

Citing Articles

Secondary Metabolites from Australian Lichens and Affect Growth and Metabolism of Photobiont through Allelopathy.

Backor M, Kecsey D, Drabova B, Urminska D, Semelakova M, Goga M Molecules. 2024; 29(19).

PMID: 39407550 PMC: 11477754. DOI: 10.3390/molecules29194620.


Are there conserved biosynthetic genes in lichens? Genome-wide assessment of terpene biosynthetic genes suggests ubiquitous distribution of the squalene synthase cluster.

Singh G, Pasinato A, Yriarte A, Pizarro D, Divakar P, Schmitt I BMC Genomics. 2024; 25(1):936.

PMID: 39375591 PMC: 11457338. DOI: 10.1186/s12864-024-10806-0.


In Silico Exploration of Isoxazole Derivatives of Usnic Acid: Novel Therapeutic Prospects Against α-Amylase for Diabetes Treatment.

Roney M, Issahaku A, Huq A, Sapari S, Abdul Razak F, Wilhelm A Cell Biochem Biophys. 2024; 82(4):3351-3366.

PMID: 39020086 DOI: 10.1007/s12013-024-01419-1.


Comparative Study on the Antimicrobial Activities and Metabolic Profiles of Five Species from the Philippines.

Cruz T, Timbreza L, Sangvichien E, Notarte K, Santiago K J Fungi (Basel). 2023; 9(11).

PMID: 37998922 PMC: 10672636. DOI: 10.3390/jof9111117.


Cytotoxic, anti-proliferative, and apoptotic evaluation of Ramalina sinensis (Ascomycota, Lecanoromycetes), lichenized fungus on oral squamous cell carcinoma cell line; in-vitro study.

Koopaie M, Karimi H, Sohrabi M, Norouzi H BMC Complement Med Ther. 2023; 23(1):296.

PMID: 37608377 PMC: 10463489. DOI: 10.1186/s12906-023-04118-1.